Rising public outcry over dramatic price increases for the life-saving allergy auto-injector EpiPen and other medications has thrown a spotlight on the role of the U.S. Food and Drug Administration, despite its lack of direct control over drug prices and competition.
On Sept. 2, Democratic presidential candidate Hillary Clinton unveiled a plan to respond to “unjustified” price hikes for drugs that have long been on the market, such as the EpiPen, calling for dedicated oversight at federal agencies to monitor drug price increases, elevating the matter to a possible campaign issue. Fines or other penalties would be leveled against companies overpricing their drugs, with funds being directed toward expanding access to new drugs and increasing competition, she said. Clinton’s plan also would allow for the emergency importation of generic drugs and other alternatives from foreign nations with high safety standards in an effort to lower costs when needed. As yet, Republican candidate Donald Trump hasn’t responded to the recent conversation on drug prices.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
